According to the risk heatmap, RBBP8 was downregulated in the high-risk group, indicating its tumor suppression potential in breast cancer, and UBE2A acted as a tumor-accelerating gene because it was upregulated in the high-risk group (Figure 2F). This evidence concerns the gene RBBP8 and breast cancer.